Immunotherapy timing for early-stage lung cancer surgery
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study compares three different schedules for giving immunotherapy (a cancer-fighting drug) to patients with early-stage non-small cell lung cancer who are having surgery. The goal is to find out which timing—before surgery, after surgery, or both—works best to prevent cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Stage II or IIIA non-small cell lung cancer that can be surgically removed, with specific genetic markers (EGFR wild type, no ALK rearrangement)
- Good overall health status (ECOG score 0–1, meaning you can do normal daily activities or have minimal limitations)
- Adequate organ function, especially lungs strong enough to handle surgery
- No prior chemotherapy, targeted therapy, or immunotherapy for this cancer
- No active tuberculosis, severe infections, HIV, or uncontrolled heart disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if receiving immunotherapy before surgery works better than getting it after surgery for people with stage II to IIIB non-small cell lung cancer. The goal is to see which timing helps prevent the cancer from coming back.
This Phase 2 trial tests an “immunotherapy” medicine given before surgery for stage III non-small cell lung cancer. The goal is to shrink the cancer and make curative surgery more successful while monitoring safety and response.
This trial looks at giving immunotherapy before surgery for certain early-stage lung cancers to help shrink the tumor and improve outcomes. It is mainly for people whose lung cancer can be removed by surgery and who don’t have specific gene changes like EGFR or ALK.
This trial tests using immunotherapy before surgery or radiation for non-small cell lung cancer. It looks at how safe and effective this approach is and how it affects survival.
This trial tests whether the timing of immunotherapy infusion before surgery improves how well the tumor responds in people with stage II to III non-small cell lung cancer. It combines immunotherapy with standard chemotherapy to shrink the tumor before it is removed.
This trial uses special tests (like looking at genes and proteins) to better understand which patients with non-small cell lung cancer (NSCLC) will benefit most from immunotherapy given before surgery. It aims to create a tool to predict treatment success.
Hear when a new Resectable Stage II-IIIa NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.